Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma

A Labrinidis; P Diamond; S Martin; S Hay; V Liapis; I Zinonos; NA Sims; GJ Atkins; C Vincent; V Ponomarev; DM Findlay; ACW Zannettino; A Evdokiou

Journal article

Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma

A Labrinidis, P Diamond, S Martin, S Hay, V Liapis, I Zinonos, NA Sims, GJ Atkins, C Vincent, V Ponomarev, DM Findlay, ACW Zannettino, A Evdokiou

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2009

DOI: 10.1158/1078-0432.CCR-08-2444

Abstract

Purpose: Multiple myeloma is an incurable disease, for which the development of new therapeutic approaches is required. Here, we report on the efficacy of recombinant soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to inhibit tumor progression and bone destruction in a xenogeneic model of human multiple myeloma. Experimental Design: We established a mouse model of myeloma, in which Apo2L/ TRAIL-sensitive RPMI-8226 or KMS-11 cells, tagged with a triple reporter gene construct (NES-HSV-TK/GFP/Luc), were transplanted directly into the tibial marrow cavity of nude mice. Tumor burden was monitored progressively by bioluminescence imaging and the development of myelom..

View full abstract